SCHEMBL481484

SCHEMBL481484

COC(=O)CCc1ccc(-c2ccc(C(C)C(O)(c3ccnc(Cl)c3)C(F)(F)F)c(Cl)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
SYK P43405 4/20 0.37
MLYCD O95822 2/20 0.36
HDAC1 Q13547 1/20 0.35
SLC13A5 Q86YT5 1/20 0.35
HRH3 Q9Y5N1 1/20 0.34
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
AAK1 Q2M2I8 2/20 0.33
CYP3A4 P08684 1/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
LMNA P02545 1/20 0.33
FFAR1 O14842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480159 0.90 FFAR1 (0.43) NR1H2NR1H3SYKSLC13A5FFAR1
SCHEMBL753191 0.90 FFAR1 (0.43) NR1H2NR1H3SYKSLC13A5FFAR1
SCHEMBL839401 0.85 SYK (0.39) NR1H2NR1H3SYK
SCHEMBL479702 0.84 ROCK2 (0.39) NR1H2NR1H3AAK1CYP3A4ROCK2
SCHEMBL15789843 0.84 ROCK2 (0.37) AAK1CYP3A4ROCK2ROCK1
SCHEMBL755473 0.84 ROCK2 (0.39) NR1H2NR1H3AAK1CYP3A4ROCK2
SCHEMBL837201 0.82 FFAR1 (0.43) NR1H2NR1H3MLYCDFFAR1
SCHEMBL479896 0.82 RXRA (0.37) SYKROCK2ROCK1
SCHEMBL752195 0.82 RXRA (0.37) SYKROCK2ROCK1
SCHEMBL15789752 0.81 AAK1 (0.38) AAK1CYP3A4ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 NR1H2 89/4885NR1H3 113/4885SYK 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.